Drug updated on 10/28/2024
| Dosage Form | Tablet (oral; 4.5 mg, 9 mg, 13.5 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test
- Indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Pemigatinib has demonstrated effectiveness in selectively targeting aberrant FGFR1, FGFR2, and FGFR3, and is specifically approved for use in patients with advanced-stage (cholangiocarcinoma).
- The data suggest potential efficacy of pemigatinib in other tumor types with Fibroblast Growth Factor Receptor (FGFR) alterations, although this is not yet its approved indication.
- The study does not provide detailed information on effectiveness across different population types or subgroups.
- There is no safety information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Pemazyre (pemigatinib) Prescribing Information. | 2023 | Incyte Corporation, Wilmington, DE |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib | 2024 | Critical Reviews in Oncology/Hematology |